The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2009N-Acetylcysteine CSF Levels and Biomarkers in a Pre-clinical Model of PD
Objective/Rationale:
N-Acetylcysteine (NAC) is an orally absorbed compound that supports neuronal synthesis of glutathione, a key neuronal antioxidant. Our objective here is to establish the blood and... -
Rapid Response Innovation Awards, 2009Generation of Dorsal Motor Nucleus (DMN) Specific Pre-clinical Model of Alpha-Synuclein Overexpression to Study Etiology of Autonomic Dysfunction in PD
Promising Outcomes of Original Grant:
According to Braak Staging of PD Pathology, the dorsal motor nucleus (DMN) is one of the earliest brain nuclei that accumulate alpha-Synuclein (aSyn) pathology... -
MJFF Research Grant, 2009Neoangiogenesis and blood-brain barrier in L-DOPA-induced dyskinesia
Promising Outcomes of Original Grant:
Working on a pre-clinical model of Parkinson´s disease, we have found that levodopa treatment induces proliferation of endothelial cells and angiogenesis in the... -
MJFF Research Grant, 2009Specific Inhibition of Nucleation of Alpha-Synuclein Aggregation as a Therapeutic Strategy
The discovery of specific genes associated with rare, genetic forms of Parkinson’s disease has opened the opportunity to investigate the mechanisms of the disease and to develop novel drugs. Parkinson...
-
Understanding LRRK2 Biology, 2009Building a LRRK2 Cohort Core Database
Objective/Rationale:
MJFF is funding the expansion of two international LRRK2 cohorts to gain insight into the relationship of this genetic mutation to Parkinson’s disease. Within each funded study... -
Target Validation, 2009Testing PDE-1 Inhibitor in MPTP-treated Macaques
Promising Outcomes of Original Grant:
Our goal is to develop novel therapeutic molecules that promote normal dopamine neurotransmission in the brain affected by PD. We hypothesize that these molecules...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.